Business Combination (Tables)
 12 Months Ended
Dec. 31, 2016
Allenex [Member]  
Schedule of Fair Values of Assets Acquired and Liabilities Assumed

The fair values of the assets acquired and liabilities assumed are as follows (in thousands):

 

 

 

Total

 

Cash

 

$

596

 

Accounts receivable

 

 

1,608

 

Prepaid and other assets

 

 

1,092

 

Inventory

 

 

9,636

 

Property, plant and equipment

 

 

1,057

 

Intangible assets

 

 

31,560

 

Goodwill

 

 

16,922

 

Deferred tax liability

 

 

(8,598

)

Assumed liabilities

 

 

(19,799

)

Total preliminary acquisition consideration

 

$

34,074

 

 
Schedule of Noncontrolling Interests

Noncontrolling interest as of December 31, 2016 was as follows (in thousands):

 

 

 

Total

 

Noncontrolling interest at January 1, 2016

 

$

—

 

Noncontrolling interest of acquired entity

 

 

634

 

Foreign currency effect

 

 

(68

)

Loss attributable to noncontrolling interest

 

 

(287

)

Noncontrolling interest at December 31, 2016

 

$

279

 

 
Summary of Identified Intangible Assets Acquired at Acquisition Date

The following table presents details of the identified intangible assets acquired at the acquisition date (in thousands):

 

 

 

Estimated

Fair Value

 

 

Estimated Useful

Life (Years)

 

Customer relationships

 

$

12,650

 

 

 

15

 

Developed technology

 

 

11,650

 

 

 

10

 

Acquired in-process technology

 

 

4,510

 

 

 

15

 

Trademarks

 

 

2,260

 

 

 

15

 

Acquired contracts

 

 

490

 

 

 

2

 

Total

 

$

31,560

 

 

 

 

 

 
Schedule of Pro Forma Results of Operations

The following table presents pro forma results of operations and gives effect to the Allenex transaction as if the transaction had been consummated on January 1, 2015. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands).

 

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

Revenue:

 

 

 

 

 

 

 

 

Testing revenue

 

$

29,681

 

 

$

27,881

 

Product revenue

 

 

15,101

 

 

 

15,957

 

Other revenue

 

407

 

 

 

578

 

Total revenue

 

$

45,189

 

 

$

44,416

 

Net loss

 

$

(32,319

)

 

$

(17,050

)

 
ImmuMetrix, Inc. [Member]  
Schedule of Pro Forma Results of Operations

The following table presents pro forma results of operations and gives effect to the IMX transaction as if the transaction had been consummated on January 1, 2013. The unaudited pro forma results of operations have been prepared for comparative purposes only and are not necessarily indicative of what would have occurred had the business combination been completed at the beginning of the period or of the results that may occur in the future. Furthermore, the pro forma financial information does not reflect the impact of any reorganization or operating efficiencies resulting from combining the two companies (in thousands).

 

 

 

Year Ended December 31,

 

 

 

2014

 

 

2013

 

Net revenue

 

$

27,306

 

 

$

22,098

 

Net loss

 

$

(1,080

)

 

$

(3,768

)